Company dossier
Vivimed Labs
NSE:VIVIMEDLAB · ISIN INE526G01021
- Close
- ₹5.29 29 Jul 2026
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Vivimed Labs
Financials
Structured filings
Exchange XBRLReported financial periods
| Metric | Quarter · 31 Dec 24 | Quarter · 30 Sept 24 | Quarter · 30 Jun 24 | Quarter · 31 Mar 24 | Quarter · 31 Dec 23 | Quarter · 30 Sept 23 |
|---|---|---|---|---|---|---|
| Revenue | ₹36.5 Cr | ₹24.8 Cr | ₹29.4 Cr | ₹38.6 Cr | N/A | N/A |
| Profit before tax | ₹-6 Cr | ₹-5.1 Cr | ₹-8.2 Cr | ₹6.7 Cr | N/A | N/A |
| Profit after tax | ₹-6 Cr | ₹-5.1 Cr | ₹-8.2 Cr | ₹5.3 Cr | N/A | N/A |
| Finance cost | ₹0.5 Cr | ₹0.4 Cr | ₹0.3 Cr | ₹-33.3 Cr | N/A | N/A |
| Impairment | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS | ₹-0.72 | ₹-0.60 | ₹-0.99 | ₹0.64 | N/A | N/A |
Accounting lens
Research frameworkWhat deserves analyst attention
Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.
Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.
Sector metrics and accounting choices require additional facts beyond this common cross-company layer.